The agreement with MFDS is an ad-hoc arrangement that focuses exclusively on COVID-19. Ad hoc agreements have a limited scope and duration and allow for the possibility to respond to specific situations. The EMA and the MFDS can thus exchange certain information without having to negotiate far-reaching, permanent confidentiality agreements. The agreement with Korea complements existing agreements with countries such as Switzerland, Canada, Japan or organisations as the EDQM and the WHO.
Pharmaceutical authorities worldwide are given the opportunity to discuss political approaches in connection with COVID-19 and regulatory adjustments through the International Coalition of Medicines Regulatory Authorities (ICMRA), which is currently chaired by the EMA. The development and approval of COVID-19 drugs and vaccines should thus be accelerated. Regular virtual meetings are being held.
EMA: News and Events
> Do not hesitate, we look forward to your feedback!
Write a comment on this news.